0001628945-23-000094 | 10-Q | XBRL Viewer

Print Document View Excel Document

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2023	May 03, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-40590
Entity Registrant Name	Cue Health Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-1562193
Entity Address, Address Line One	4980 Carroll Canyon Rd.
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	412-8151
Title of 12(b) Security	Common Stock, par value $0.00001 per share
Trading Symbol	HLTH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		151,618,769
Entity Central Index Key	0001628945
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 178,201	$ 241,530
Restricted cash	800	800
Accounts receivable, net	9,799	18,751
Inventories, net - current	82,006	82,210
Prepaid expenses	11,617	15,728
Other current assets	4,574	12,134
Total current assets	286,997	371,153
Non-current inventories, net	27,718	25,436
Property and equipment, net	184,197	189,275
Operating lease right-of-use assets	84,542	85,321
Intangible assets, net	19,774	16,867
Other non-current assets	5,333	6,528
Total assets	608,561	694,580
Current liabilities:
Accounts payable	16,644	7,150
Accrued liabilities and other current liabilities	40,173	52,378
Deferred revenue, current	754	1,566
Operating lease liabilities, current	7,739	7,739
Finance lease liabilities, current	2,148	2,362
Total current liabilities	67,458	71,195
Operating leases liabilities, net of current portion	42,826	44,045
Finance lease liabilities, net of current portion	417	849
Other non-current liabilities	1,997	1,997
Total liabilities	112,698	118,086
Commitments and contingencies (Note 15)
Stockholders’ Equity
Common stock, $0.00001 par value; 500,000,000 and 500,000,000 shares authorized, 151,567,650 and 150,406,014 issued and outstanding at March 31, 2023 and December 31, 2022, respectively	2	1
Additional paid-in-capital	808,133	794,567
Accumulated deficit	(312,272)	(218,074)
Total stockholders’ equity	495,863	576,494
Total liabilities and stockholders’ equity	$ 608,561	$ 694,580

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	151,567,650	150,406,014
Common stock, shares outstanding (in shares)	151,567,650	150,406,014

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue
Revenue	$ 24,765	$ 179,410
Operating costs and expenses:
Sales and marketing	11,248	34,168
Research and development	44,733	28,787
General and administrative	16,938	26,910
Restructuring expense	7,873	0
Total operating costs and expenses	120,615	176,562
(Loss) income from operations	(95,850)	2,848
Interest expense	(220)	(51)
Other income, net	1,872	6
Net (loss) income before income taxes	(94,198)	2,803
Income tax (benefit) expense	0	0
Net (loss) income	$ (94,198)	$ 2,803
Net (loss) income per share – basic (in dollars per share)	$ (0.62)	$ 0.02
Weighted-average number of shares used in computation of net (loss) income per share – basic (in shares)	151,083,716	146,526,370
Net (loss) income per share – diluted (in dollars per share)	$ (0.62)	$ 0.02
Weighted-average number of shares used in computation of net (loss) income per share – diluted (in shares)	151,083,716	153,036,804
Product revenue
Revenue
Revenue	$ 24,494	$ 177,454
Operating costs and expenses:
Cost of product revenue	39,823	86,697
Grant and other revenue
Revenue
Revenue	$ 271	$ 1,956

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021		146,402,991
Beginning balance at Dec. 31, 2021	$ 706,750	$ 1	$ 730,767	$ (24,018)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock options (in shares)		294,856
Exercise of common stock options	270		270
Issuance of common stock upon vesting of restricted stock units (in shares)		930,493
Tax withholding on exercise of stock options and issuance of shares from restricted stock units (shares)		(670,044)
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation	(720)		(720)
Stock-based compensation	16,035		16,035
Net (loss) income	2,803			2,803
Ending balance (in shares) at Mar. 31, 2022		146,958,296
Ending balance at Mar. 31, 2022	$ 725,138	$ 1	746,352	(21,215)
Beginning balance (in shares) at Dec. 31, 2022	150,406,014	150,406,014
Beginning balance at Dec. 31, 2022	$ 576,494	$ 1	794,567	(218,074)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of common stock options (in shares)	142,141	1,075,820
Exercise of common stock options	$ 96	$ 1	95
Issuance of common stock upon vesting of restricted stock units (in shares)		398,470
Tax withholding on exercise of stock options and issuance of shares from restricted stock units (shares)		(312,654)
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation	(924)		(924)
Stock-based compensation	14,407		14,407
Other	(12)		(12)
Net (loss) income	$ (94,198)			(94,198)
Ending balance (in shares) at Mar. 31, 2023	151,567,650	151,567,650
Ending balance at Mar. 31, 2023	$ 495,863	$ 2	$ 808,133	$ (312,272)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net (loss) income	$ (94,198)	$ 2,803
Adjustments to reconcile net (loss) income to net cash, cash equivalents and restricted cash (used in) provided by operations
Depreciation and amortization	12,064	10,606
Allowance for doubtful accounts provision	312	(229)
Stock-based compensation expense	14,407	16,035
Non-cash lease expense	2,278	1,996
Interest on finance leases	24	51
Non-cash interest expense	79	65
Changes in operating assets and liabilities:
Accounts receivable	8,640	28,988
Inventories	(2,078)	(44,179)
Prepaid expenses and other current assets	11,659	1,618
Other non-current assets	1,116	(1,876)
Accounts payable, accrued liabilities and other current liabilities	(4,656)	18,254
Deferred revenue	(812)	2,464
Operating lease liabilities	(2,718)	(5,075)
Net cash, cash equivalents and restricted cash (used in) provided by operating activities	(53,883)	31,521
Cash flows from investing activities
Purchase of property and equipment	(3,906)	(12,782)
Expenditures for software development	(4,412)	(1,273)
Net cash, cash equivalents and restricted cash used in investing activities	(8,318)	(14,055)
Cash flows from financing activities
Proceeds from exercise of common stock options	96	270
Tax withholding on exercise of stock options	(924)	(720)
Proceeds from employee stock purchase plan activity	370	273
Payments for finance leases	(670)	(696)
Net cash, cash equivalents and restricted cash used in financing activities	(1,128)	(873)
Net change in cash, cash equivalents and restricted cash	(63,329)	16,593
Cash, cash equivalents and restricted cash, beginning balance	242,330	423,710
Cash, cash equivalents and restricted cash, ending balance	179,001	440,303
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents	178,201	426,465
Restricted cash	800	13,838
Total cash, cash equivalents and restricted cash	179,001	440,303
Supplemental disclosure for cash flow information
Cash paid for taxes	0	0
Cash paid for interest	0	0
Supplemental disclosure for non-cash investing and financing matters
Right-of-use assets obtained in exchange for lease obligations	0	2,611
Prepaid rent reclassified to right-of-use assets	0	50
Purchase of property and equipment included in accounts payable	2,548	9,235
Software development costs included in accounts payable	$ 0	$ 897

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) (Unaudited) (Parenthetical)	3 Months Ended
	Mar. 31, 2023 shares
Statement of Stockholders' Equity [Abstract]
Exercise of common stock options, including ESPP activity (in shares)	473,080

BUSINESS AND BASIS OF ACCOUNTING	3 Months Ended
BUSINESS AND BASIS OF ACCOUNTING	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS AND BASIS OF ACCOUNTING	BUSINESS AND BASIS OF ACCOUNTING Organization and Description of Business Cue Health Inc. (the “Company”) was originally formed in the State of California on January 26, 2010, prior to being incorporated in the State of Delaware on December 14, 2017. The Company is a healthcare technology company committed to revolutionizing the healthcare experience by providing individuals with a convenient and connected diagnostic platform that bridges the physical and virtual care continuum. The Company’s proprietary platform, the Cue Health Monitoring System, comprised of the Cue Reader and Cue Test Kit, enables lab-quality diagnostics-led care at home, at work or at the point of care. This platform is designed to empower stakeholders across the healthcare ecosystem, including individuals, enterprises, healthcare providers and payors, and public health agencies with paradigm-shifting access to diagnostic and health data to inform care decisions. The Company’s headquarters are located in San Diego, California. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited annual financial statements and notes thereto for the year ended December 31, 2022. The unaudited interim condensed consolidated balance sheet as of December 31, 2022 included herein was derived from the audited financial statements as of that date. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results for the fiscal year ending December 31, 2023 or any future interim period. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim reporting and, in the opinion of management, include all adjustments necessary for the fair statement of the Company’s financial position for the periods presented. All such adjustments are of a normal, recurring nature. Certain disclosures have been condensed or omitted from the interim condensed consolidated financial statements. The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, income and expenses as well as the related disclosure of contingent assets and liabilities. Use of Estimates The preparation of the accompanying unaudited interim condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, net accounts receivable, equity-based compensation expense, product warranty reserve, the usage and recoverability of its inventories and long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates. Segment Reporting Operating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. In addition, the guidance for segment reporting indicates certain quantitative materiality thresholds. The Company views its operations and manages its business in one operating segment which is consistent with how the Chief Executive Officer, who is the chief operating decision-maker, reviews the business, makes investment and resource allocation decisions, and assesses operating performance. The majority of revenue to date is from customers located in the United States and the majority of long-lived assets are located in the United States. Revenues to customers located outside of the United States were not material and $3.5 million for the three months ended March 31, 2023 and 2022, respectively. Long-lived assets, which consist of property and equipment, located outside of the United States were $4.4 million and $4.7 million as of March 31, 2023 and December 31, 2022, respectively. COVID-19 Impact COVID-19 was declared a global pandemic by the World Health Organization in March 2020 and adversely impacted global commercial activity but served as a catalyst to accelerating the Company’s product pipeline. The Company began selling and recording product revenues for its Cue COVID-19 test in August 2020 after obtaining an EUA from the FDA in June 2020. Currently, the majority of the Company’s product revenues are derived from the Cue COVID-19 test. Given the unpredictable nature of the COVID-19 pandemic, the development and potential size of the COVID-19 diagnostic testing market is highly uncertain. The FDA issued various EUAs and approvals for COVID-19 vaccines. The widely administered use of an efficacious vaccine or new therapeutic treatment for COVID-19 may reduce the demand for the Cue COVID-19 test and, as a result, the COVID-19 diagnostic testing market may not develop or grow substantially. Given the rapid development of events surrounding the pandemic, there is uncertainty to the Company’s future results and performance.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Mar. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES There have been no material changes to the Company's significant accounting policies from its Annual Report on Form 10-K for the fiscal year ended December 31, 2022. Recent Accounting Pronouncements In September 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments. The standard provides guidance for estimating credit losses on certain types of financial instruments, including trade receivables, by introducing an approach based on expected losses. The expected loss approach will require entities to incorporate considerations of historical information, current information and reasonable and supportable forecasts. ASU 2016-13 also amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. The Company adopted this standard effective January 1, 2023 under the modified retrospective method whereas comparative period information is not restated. The adoption of this standard did not have a significant impact on the Company’s condensed consolidated financial statements, therefore no cumulative effect or catch up adjustment to the opening balance of retained earnings was recorded.

REVENUE

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

REVENUE

Product Revenue

Disaggregation of the product revenue by type of customer for the three months ended March 31, 2023 and 2022, respectively:


	Three Months Ended March 31,
		2023		2022
Private sector customers		$	24,013	$	175,844
Public sector entities		481		1,610
Total product revenue		$	24,494	$	177,454

Product revenue for the three months ended March 31, 2023 includes an immaterial amount of service revenue generated from telemedicine and proctoring services provided to customers. Revenue generated from proctoring is recognized over the term of the contracts with customers.

The following table sets forth the Company’s product gross (loss) profit and product gross (loss) profit margin for the three months ended March 31, 2023 and 2022:


	Three Months Ended March 31,
		2023			2022
Product revenue		$	24,494		$	177,454
Cost of product revenue		39,823			86,697
Product gross (loss) profit		$	(15,329)		$	90,757
Product gross (loss) profit margin		(63)		%	51		%

During the three months ended March 31, 2023, a contract manufacturer vendor drew on a cash collateralized letter of credit in the amount of $12.0 million (the “disputed payment charge”) that was recorded in cost of product revenue. The Company disputes the validity of the payment and is pursuing recovery.

Contract Assets and Liabilities

Contract assets primarily relate to the Company’s conditional right to consideration for performance obligations satisfied through direct-to-consumer sales but not billed at the reporting date. Net contract assets were not material and $0.3 million as of March 31, 2023 and December 31, 2022, respectively, and were recorded in other current assets on the balance sheets.

Contract liabilities are recorded when cash is received prior to recording revenue. Contract liabilities are recorded in deferred revenue on the balance sheets. The activity related to contract liabilities for the three months ended March 31, 2023 and 2022 is as follows:


	Three Months Ended March 31,
	2023		2022
Balance at beginning of period	$	1,566	$	92,448
Unearned revenue from cash received during the period, excluding amounts recognized as revenue during the period	556		2,464
Revenue recognized related to contract liability balance at the beginning of the period	(1,368)		—
Balance at end of period	$	754	$	94,912

Grant and Other Revenue

Grant and other revenue primarily relates to a cost reimbursement agreement with the Biomedical Advanced Research and Development Authority (“BARDA”). The Company generated $0.1 million and $2.0 million of revenue related to the agreement with BARDA during the three months ended March 31, 2023 and 2022, respectively.

Accounts Receivable

Under ASU 2016-13, the Company is required to remeasure expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The allowance for doubtful accounts represents the Company’s estimate of expected credit losses relating to these factors. Amounts are written off against the allowances for doubtful accounts when the Company determines that a customer account is uncollectible. As of March 31, 2023 and December 31, 2022, the Company’s allowance for doubtful accounts was $2.0 million and $2.3 million, respectively.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

INVENTORIES

3 Months Ended

Mar. 31, 2023

Inventory Disclosure [Abstract]

INVENTORIES

As of March 31, 2023 and December 31, 2022, the Company’s inventories consisted of the following:


	March 31, 2023		December 31, 2022
Raw materials	$	80,939	$	80,968
Work-in-process	12,647		14,305
Finished goods	45,061		37,867

Reserve	(28,923)		(25,494)
Total inventories	$	109,724	$	107,646
Non-current inventories	$	(27,718)	$	(25,436)
Total inventories, current	$	82,006	$	82,210

PREPAID EXPENSES

3 Months Ended

Mar. 31, 2023

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

PREPAID EXPENSES

As of March 31, 2023 and December 31, 2022, the Company’s prepaid expenses consisted of the following:


	March 31, 2023		December 31, 2022
Prepaid expense	$	7,892	$	11,523
Prepaid inventory	3,725		4,205
Total prepaid expenses	$	11,617	$	15,728

PROPERTY AND EQUIPMENT, NET

3 Months Ended

Mar. 31, 2023

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT, NET

As of March 31, 2023 and December 31, 2022, the Company’s property and equipment, net consisted of the following:


	March 31, 2023		December 31, 2022
Construction in progress	$	36,101	$	32,412
Machinery and equipment	216,355		214,702
Leasehold improvements	23,343		23,233
Furniture and fixtures	1,911		1,883
Property and equipment	277,710		272,230
Accumulated depreciation and amortization	(93,513)		(82,955)
Total property and equipment, net	$	184,197	$	189,275

Depreciation and amortization expense related to property and equipment was $10.6 million and $10.0 million for the three months ended March 31, 2023 and 2022, respectively. The carrying value of assets under finance leases within property and equipment as of March 31, 2023 and December 31, 2022 was $6.6 million and $7.3 million, respectively.

As of March 31, 2023, the carrying value of manufacturing equipment not yet placed into service was $23.8 million. The cost of this equipment is substantially complete and is included in construction in progress. Depreciation expense related to these assets will commence when they are placed into service and will be depreciated over their estimated useful lives.

INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

As of March 31, 2023 and December 31, 2022, the Company’s intangible assets consisted of the following:


	March 31, 2023		December 31, 2022
Capitalized software	$	18,658	$	19,052
Accumulated amortization	(7,229)		(5,724)
Capitalized software, net	11,429		13,328
In-process software development	8,345		3,539
Total intangible assets	$	19,774	$	16,867

During the development stage, the Company capitalizes certain eligible costs associated with the software development, in accordance with ASC 350-40, Internal-Use Software. The capitalized costs primarily consist of direct labor and third-party contractor fees. In-process software development consists of software costs incurred in the development of internal-use software not yet implemented. The software is expected to be implemented no later than one year from the commencement date of development. Once the software is implemented and ready for its intended use, the Company will begin amortizing the capitalized costs on a straight-line basis over the software's estimated useful life.

Amortization expense related to intangible assets placed in service was $1.6 million and $0.6 million for the three months ended March 31, 2023 and 2022, respectively. Estimated amortization expense for each of the years ending December 31 is as follows:


2023 (excluding the three months ended March 31, 2023)	$	4,409
2024	5,073
2025	1,937
2026	10
Total amortization expense	$	11,429

LEASES

3 Months Ended

Mar. 31, 2023

Leases [Abstract]

LEASES

The Company leases real estate and manufacturing and laboratory equipment which are used in the Company’s manufacturing, research and development, and administrative activities. The Company identifies a contract that contains a lease as one which conveys a right, either explicitly or implicitly, to control the use of an identified asset in exchange for consideration. These arrangements are classified as finance leases and operating leases. Finance leases consist of laboratory and manufacturing equipment with remaining terms ranging from under 1 year to 2 years. The Company’s operating leases relate to the Company’s manufacturing facilities and office space and have remaining terms from under 1 year to 9 years.

There were no new material leases entered into during the three months ended March 31, 2023.

The right-of-use assets and lease liabilities recognized on the Company’s balance sheet as of March 31, 2023 and December 31, 2022 were as follows:


	Balance Sheet Location	March 31, 2023		December 31, 2022
Assets
Right-of-use assets operating leases	Operating lease right-of-use assets	$	84,542	$	85,321
Right-of-use assets finance leases	Property and equipment, net	6,624		7,264
Liabilities
Operating lease liabilities (current)	Operating lease liabilities, current	7,739		7,739
Finance lease liabilities (current)	Finance lease liabilities, current	2,148		2,362
Operating lease liabilities (non-current)	Operating lease liabilities, net of current portion	42,826		44,045
Finance lease liabilities (non-current)	Finance lease liabilities, net of current portion	417		849

The components of lease expense for the three months ended March 31, 2023 and 2022 were as follows:


	Three Months Ended March 31,
		2023		2022
Operating lease cost		$	2,988	$	2,762
Finance lease cost:
Amortization of right-of-use assets		640		639
Interest on lease liabilities		24		51
Total lease cost		$	3,652	$	3,452

LEASES

There were no new material leases entered into during the three months ended March 31, 2023.

The right-of-use assets and lease liabilities recognized on the Company’s balance sheet as of March 31, 2023 and December 31, 2022 were as follows:


	Balance Sheet Location	March 31, 2023		December 31, 2022
Assets
Right-of-use assets operating leases	Operating lease right-of-use assets	$	84,542	$	85,321
Right-of-use assets finance leases	Property and equipment, net	6,624		7,264
Liabilities
Operating lease liabilities (current)	Operating lease liabilities, current	7,739		7,739
Finance lease liabilities (current)	Finance lease liabilities, current	2,148		2,362
Operating lease liabilities (non-current)	Operating lease liabilities, net of current portion	42,826		44,045
Finance lease liabilities (non-current)	Finance lease liabilities, net of current portion	417		849

The components of lease expense for the three months ended March 31, 2023 and 2022 were as follows:


	Three Months Ended March 31,
		2023		2022
Operating lease cost		$	2,988	$	2,762
Finance lease cost:
Amortization of right-of-use assets		640		639
Interest on lease liabilities		24		51
Total lease cost		$	3,652	$	3,452

ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES

3 Months Ended

Mar. 31, 2023

Payables and Accruals [Abstract]

ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES

Accrued liabilities and other current liabilities consisted of the following:


	March 31, 2023		December 31, 2022
Accrued purchases(1)	$	2,517	$	4,488
Accrued payroll and benefits	14,211		26,350
Accrued expenses	7,894		5,553
Accrued sales tax	385		1,361
Product warranty reserve (See Note 15. Commitments and Contingencies)	6,584		6,660
Accrued restructuring	365		—
Accrued purchase commitment loss (2)	8,217		7,966
Total accrued liabilities and other current liabilities	$	40,173	$	52,378

(1) Accrued purchases primarily reflects receipts of goods and services for which we had not yet been invoiced. As we are invoiced for these goods and services, this balance will reduce and accounts payable will increase.

(2) Accrued purchase commitment loss reflects accrued loss on purchase obligations for inventory expected to be reserved.

DEBT	3 Months Ended
DEBT	Mar. 31, 2023
Debt Disclosure [Abstract]
DEBT	DEBT Secured Revolving Facility Agreement On June 30, 2022, the Company entered into a loan and security agreement (the “2022 Revolving Facility Agreement”) among the Company, the lenders from time to time party thereto and East West Bank, as collateral agent and administrative agent (“Agent”). The 2022 Revolving Facility Agreement provides for a $100.0 million secured revolving credit facility, with a $20.0 million letter of credit subfacility. As of March 31, 2023, there were no revolving loans outstanding and $1.0 million aggregate face amount of letters of credit outstanding under the 2022 Revolving Facility Agreement, which reduces the availability to borrow under the revolving credit facility to $99.0 million. The Company recorded $0.6 million in deferred financings costs in connection with the 2022 Revolving Facility Agreement. This balance is amortized over two years and is classified in other non-current assets since no funds were drawn on the 2022 Revolving Facility Agreement. The revolving loans are available subject to the Company maintaining an asset coverage ratio of not less than 1.20 to 1.00, measured as (x) the sum of specified cash and cash equivalents subject to liens in favor of Agent plus 80% of eligible accounts receivable less the amount of the Company’s outstanding sales tax liability to (y) the principal amount of the outstanding obligations under the 2022 Revolving Facility Agreement. The revolving commitments terminate and the principal amount of outstanding revolving loans, together with accrued and unpaid interest, is due and payable on June 30, 2024. The revolving loans accrue interest at the greater of the prime rate and 3.50%. Interest on the revolving loans is payable monthly in arrears. The Company may borrow, prepay and reborrow revolving loans, without premium or penalty. The Company is required to pay a prepayment fee of 1.0% if the revolving commitments are terminated prior to the maturity date. The Company is also obligated to pay other customary fees for a loan facility of this size and type. The Company’s obligations under the 2022 Revolving Facility Agreement are secured by substantially all of the Company’s assets, and will be guaranteed by, and secured by substantially all of the assets of, its future domestic subsidiaries. As of the closing date, there were no guarantors. The 2022 Revolving Facility Agreement requires the Company to maintain a current ratio of not less than 1.20 to 1.00, measured quarterly. The 2022 Revolving Facility Agreement also requires the Company to maintain at least six months remaining liquidity, determined as set forth in the 2022 Revolving Facility Agreement. Additionally, the 2022 Revolving Facility Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries to, among other things, dispose of assets, effect certain mergers, incur debt, grant liens, pay dividends and distributions on their capital stock, make investments and acquisitions, and enter into transactions with affiliates, in each case subject to customary exceptions for a loan facility of this size and type. The Company was in compliance with its covenants as of March 31, 2023. The events of default under the 2022 Revolving Facility Agreement include, among others, payment defaults, material misrepresentations, breaches of covenants, cross defaults with certain other material indebtedness, bankruptcy and insolvency events, the occurrence of a material adverse effect, a change of control and judgment defaults. The occurrence of an event of default could result in the acceleration of the Company’s obligations under the 2022 Revolving Facility Agreement, the termination of the lenders’ commitments, a 2% increase in the applicable rate of interest and the exercise by Agent and the lenders of other rights and remedies provided for under the 2022 Revolving Facility Agreement or applicable law.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

CAPITAL STOCK	3 Months Ended
CAPITAL STOCK	Mar. 31, 2023
Equity [Abstract]
CAPITAL STOCK	CAPITAL STOCK Common Stock Warrants As of March 31, 2023, the Company had an outstanding warrant to purchase 75,744 shares of common stock at a purchase price of $0.40 per share. The warrant was issued on August 22, 2017 and expires on August 22, 2027. All shares subject to the warrant were vested as of December 31, 2022.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

STOCK-BASED COMPENSATION

3 Months Ended

Mar. 31, 2023

Share-Based Payment Arrangement [Abstract]

STOCK-BASED COMPENSATION

Stock Incentive Plans

2021 Stock Incentive Plan

In September 2021, the Company adopted the 2021 Stock Incentive Plan (“2021 Plan”) under which employees, officers and directors, as well as consultants and advisors to the Company are eligible to be granted awards (incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards). The 2021 Plan initially authorized the issuance of a maximum of 22,399,691 shares of common stock. The number of shares of common stock available for issuance under the 2021 Plan were and will be increased on the first day of each fiscal year beginning with the 2022 fiscal year, in an amount equal to the least of (i) 5% of the number of shares of the Company's common stock outstanding on the first day of such fiscal year and (ii) the number of shares of the Company's common stock determined by the Company's board of directors.

2021 Employee Stock Purchase Plan

In September 2021, the Company adopted the 2021 Employee Stock Purchase Plan (“2021 ESPP”) under which employees of the Company can purchase shares of the Company’s common stock commencing on such time and such dates as the board of directors of the Company determine. The 2021 ESPP initially allowed for the sale of 2,834,754 shares of common stock. The number of shares of the Company's common stock to be sold under the 2021 ESPP were and will be increased on the first day of each fiscal year beginning with the 2022 fiscal year, in an amount equal to the least of (i) 8,504,263 shares, (ii) 1% of the number of shares of the Company's common stock outstanding on the first day of such fiscal year and (ii) a number of shares of the Company's common stock determined by the Company's board of directors. The price at which stock is purchased under the 2021 ESPP is equal to 85% of the fair market value of the Company’s common stock on the lesser of either (i) the first business day of the Plan Period or (ii) the Exercise Date.

Stock-Based Compensation

Stock-based compensation expense related to awards issued under the Company's incentive compensation plans for the three months ended March 31, 2023 and 2022, was as follows:


	Three Months Ended March 31,
		2023		2022
Cost of product revenues		$	636	$	518
Sales and marketing		1,528		2,813
Research and development		5,069		5,145
General and administrative		6,855		7,559
Restructuring		319		—
Total stock-based compensation expense		$	14,407	$	16,035

In total, $0.6 million of stock-based compensation expense was capitalized to inventory during the manufacturing process during the three months ended March 31, 2023. An immaterial amount remained in inventory as of March 31, 2023.

Stock Options

A summary of stock option activity and related information for the three months ended March 31, 2023 was as follows:


	Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)
Outstanding at January 1, 2023	7,102,853	$	5.92	6.4
Granted	3,473,387	2.15
Exercised	(142,141)	0.70
Forfeited	(754,996)	14.37
Expired	(5,500)	15.61
Outstanding at March 31, 2023	9,673,603	$	3.97	7.4
Exercisable at March 31, 2023	5,587,957	$	4.42	5.7
Vested and expected to vest at March 31, 2023	9,673,603	$	3.97	7.4

As of March 31, 2023, there was approximately $11.3 million of unamortized compensation cost related to unvested stock option awards, which is expected to be recognized over a remaining weighted-average vesting period of 2.6 years, on a straight-line basis.

The estimated fair value of each stock option award granted to employees was determined on the date of grant using the BSM option pricing model with the following assumptions for stock option grants for the three months ended March 31, 2023.


	2023
Expected volatility	85%
Expected term (years)	6.5
Expected dividend yield	0.0%
Risk-free interest rate	4.3%
Grant date fair value	$	1.58

During the three months ended March 31, 2023, the Company modified certain stock options previously granted to non-employees. The modification included changes to the exercise price of 622,323 unvested options. As a result of these modifications, the Company will recognize an additional $0.4 million in stock-based compensation expense over the remaining vesting period of the affected options.

Restricted Stock Units

Under the 2014 and 2021 Plans, RSUs are generally subject to a 4-year vesting period, with 25% of the shares vesting one year from the vesting commencement date and quarterly thereafter over the remaining vesting term, but may be subject to other vesting conditions such as performance or market based conditions. Compensation expense is recognized ratably over the requisite service period.

A summary of RSU activity and related information for the three months ended March 31, 2023 was as follows:


	Underlying Shares	Weighted-average Grant Date Fair Value		Aggregate Fair Value
Outstanding, January 1, 2023	18,681,701	$	9.51	$	177,739
Granted	6,821,951	2.11		14,370
Vested	(864,455)	10.29		(8,893)
Forfeited	(2,038,728)	6.28		(12,797)
Outstanding, March 31, 2023	22,600,469	$	7.54	$	170,419

As of March 31, 2023, there was approximately $123.5 million of total unrecognized compensation cost related to outstanding RSUs, which is expected to be recognized over a remaining weighted-average vesting period of 2.9 years, on a straight-line basis.

Market-Based Performance-Vesting RSUs

In September 2021, the Company issued 3,335,300 RSUs that vest based on the satisfaction of both a continued employment condition and the achievement of certain market-based performance goals. Market-based performance-vesting RSUs vest upon the achievement of certain stock price performance over a performance period. There are seven stock price targets which can be achieved over the performance period and are based on an average closing price of the Company’s common stock.

Market-based performance-vesting RSU activity for the three months ended March 31, 2023 was as follows:


	Underlying Shares		Weighted-average Grant Date Fair Value		Aggregate Fair Value
Outstanding, January 1, 2023	$	3,335,300	$	12.82	$	42,759
Granted	—		—		—
Vested	—		—		—
Forfeited	—		—		—
Outstanding, March 31, 2023	$	3,335,300	$	12.82	$	42,759

Operational-Based Performance-Vesting RSUs

In September 2021, the Company issued 1,597,272 operational-based performance-vesting RSUs that vest based on the satisfaction of both a continued employment condition and the achievement of certain performance goals including meeting certain annual revenue targets and product development milestones.

The grant date fair value of operational-based performance-vesting RSUs was estimated based on the fair value of the Company’s common stock on the date of grant. Compensation costs are recorded when achievement of the performance goals is determined to be probable.

Operations-based performance-vesting RSU activity for the three months ended March 31, 2023 was as follows:


	Underlying Shares	Weighted-average Grant Date Fair Value		Aggregate Fair Value
Outstanding, January 1, 2023	798,635	$	16.00	$	12,778
Granted	266,212	2.48		660
Vested	—	—		—
Forfeited	(266,212)	2.48		(660)
Outstanding, March 31, 2023	798,635	$	16.00	$	12,778

INCOME (LOSS) PER SHARE

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

INCOME (LOSS) PER SHARE

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average common shares outstanding during the period. Diluted net income (loss) per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method and the if-converted method. Dilutive potential common shares include stock options, non-vested shares, redeemable convertible preferred shares, convertible notes, restricted stock and similar equity instruments granted by the Company. Some restricted stock units vest upon certain performance and market conditions and as they vest, the shares will be included in outstanding common shares. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive.

The following table reconciles net (loss) income and the weighted-average shares used in computing basic and diluted earnings per share:


	Three Months Ended March 31,
		2023		2022
Numerator:
Net (loss) income		$	(94,198)	$	2,803






Denominator:
Basic weighted-average common shares outstanding		151,083,716		146,526,370
Dilutive potential common stock issuable:
Common stock warrants		—		72,395

Stock options		—		5,813,101
Restricted stock units		—		624,938
Diluted weighted-average shares outstanding		151,083,716		153,036,804

Net (loss) income per share
Basic		$	(0.62)	$	0.02
Diluted		$	(0.62)	$	0.02

In periods of net losses, potentially dilutive securities are not included in the calculation of diluted net income (loss) per share because to do so would be anti-dilutive.

Outstanding anti-dilutive securities not included in the diluted net income (loss) per share attributable to common stockholders calculations were as follows (in common stock equivalent shares):


	Three Months Ended March 31,
		2023	2022

Stock options		9,673,603	2,701,855
Restricted stock units		22,600,469	9,634,182



Employee stock purchase plan – shares projected to be issued		564,413	110,935
Total		32,838,485	12,446,972

INCOME TAXES	3 Months Ended
INCOME TAXES	Mar. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective income tax rate for each of the three months ended March 31, 2023 and 2022 was 0%. The effective tax rate for the three months ended March 31, 2023 and 2022, differs from the statutory rate primarily due to the Company maintaining a full valuation allowance against its net deferred tax assets.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

Product Liability

The Company’s business exposes it to liability risks from its potential medical diagnostic products. Product liability claims could result in the payment of significant amounts of money and divert management’s attention from running the business. The Company may not be able to maintain insurance on acceptable terms, or the insurance may not provide adequate protection in the case of a product liability claim. To the extent that product liability insurance, if available, does not cover potential claims, the Company would be required to self-insure the risks associated with such claims. The Company believes it carries reasonably adequate insurance for product liability.

Product Warranty Reserve

The Company provides its customers with the right to receive a replacement of defective or nonconforming Cue Readers for a period of up to twelve months from the date of shipment. Subject to certain limitations, the Company currently provides customers with the right to receive a replacement Cue Cartridge for tests that do not produce a valid result, for a period of up to ninety days from the date the test is performed. All warranties are classified as current liabilities within the accrued liabilities and other current liabilities on the balance sheet. Provisions for estimated expenses related to product warranty are made at the time products are sold. These estimates are determined based on historical information that includes test failure rates, replacement frequency, and the overall replacement cost. The Company evaluates the reserve on a quarterly basis and makes adjustments when appropriate. Changes to test failure rates and overall replacement rates could have a material impact on our estimated liability.

The following table provides a reconciliation of the change in estimated warranty liabilities:


	Amount
Balance, December 31, 2022	$	6,660
Provision for warranties	3,322
Settlements	(3,398)
Balance, March 31, 2023	$	6,584

Cost Reduction Plan

On January 5, 2023, the Company announced that it was implementing a new cost reduction plan (the “CRP”). Management, with the oversight and guidance of the Company’s board of directors, determined to implement the CRP following a review of the Company’s business, operating expenses and the macroeconomic environment. The CRP is

intended to reduce the Company’s cost structure and improve its operational efficiency. The CRP includes a reduction in the Company’s employee base.

Cash expenditures in connection with the CRP consist of payments for salary, benefits, and unused paid time off for the affected employees. The CRP will also consist of a severance package that includes a cash severance payment and payments to cover the employer premiums and administration fees for continuation of healthcare coverage for a limited period. The severance package, in some cases, will also include an acceleration of the vesting of certain outstanding restricted stock units and stock options to affected employees.

Each affected employee’s eligibility for the severance benefits is contingent upon such employee’s execution (and no revocation) of a separation agreement, which includes a general release of claims against the Company. The Company expects payments relating to the CRP to be completed by the end of the second quarter of 2023.

In connection with the CRP, the Company recorded a $7.9 million restructuring charge related to one-time termination benefits during the three months ended March 31, 2023.

The following table summarizes the total amount incurred and accrued related to these restructuring activities:


	Amount
Accrued restructuring as of December 31, 2022	$	—
Restructuring charges incurred during the period	7,873
Cash payments	(7,247)
Non-cash settlements and other adjustments	(261)
Accrued restructuring as of March 31, 2023	$	365

On April 28, 2023, the Company announced a further cost reduction plan, which will include a reduction in the Company’s employee base. In connection with this cost reduction plan, the Company estimates that it will record an aggregate restructuring charge related to one-time termination benefits in the range of approximately $5.0 million to $7.0 million during the three months ended June 30, 2023. The substantial majority of these charges will result in cash expenditures. The Company expects payments relating to the further cost reduction plan to be completed by the end of the fourth quarter of 2023.

Standby Letters of Credit

The 2022 Revolving Facility Agreement provides for a $100.0 million secured revolving credit facility, with a $20.0 million letter of credit subfacility. As of March 31, 2023, there were no revolving loans outstanding and $1.0 million aggregate face amount of letters of credit outstanding under the 2022 Revolving Facility Agreement, which reduces the availability to borrow under the revolving credit facility to $99.0 million.

Restricted Cash

In November 2021, $0.8 million of cash was restricted in relation to a customs surety on international imports which remains restricted as of March 31, 2023.

Purchase Commitments

Purchase commitments are comprised of the Company’s commitments for goods and services in the normal course of business. These purchase commitments relate to goods and services which have not yet been delivered or performed and therefore have not been reflected in our condensed consolidated balance sheets and condensed consolidated statements of operations. These commitments typically become due after the delivery and completion of such goods or services.

TrustedMedRx Acquisition

On March 22, 2023, CHP HC, LLC, a wholly-owned subsidiary of the Company, entered into a definitive agreement to acquire TrustedMedRx, LLC, a privately-held pharmacy. The acquisition was completed on May 4, 2023, and is expected to enhance the Company's presence in the retail pharmacy market and expand its product and service offerings.

The total purchase price for the acquisition is approximately $0.7 million, which will be funded through the Company's existing cash resources.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of PresentationThe accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited annual financial statements and notes thereto for the year ended December 31, 2022. The unaudited interim condensed consolidated balance sheet as of December 31, 2022 included herein was derived from the audited financial statements as of that date. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results for the fiscal year ending December 31, 2023 or any future interim period. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim reporting and, in the opinion of management, include all adjustments necessary for the fair statement of the Company’s financial position for the periods presented. All such adjustments are of a normal, recurring nature. Certain disclosures have been condensed or omitted from the interim condensed consolidated financial statements. The preparation of the accompanying financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, income and expenses as well as the related disclosure of contingent assets and liabilities.
Use of Estimates	Use of Estimates The preparation of the accompanying unaudited interim condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to revenue recognition, net accounts receivable, equity-based compensation expense, product warranty reserve, the usage and recoverability of its inventories and long-lived assets and net deferred tax assets (and related valuation allowance). The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.
Segment Reporting	Segment ReportingOperating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. In addition, the guidance for segment reporting indicates certain quantitative materiality thresholds. The Company views its operations and manages its business in one operating segment which is consistent with how the Chief Executive Officer, who is the chief operating decision-maker, reviews the business, makes investment and resource allocation decisions, and assesses operating performance. The majority of revenue to date is from customers located in the United States and the majority of long-lived assets are located in the United States.
Recent Accounting Pronouncements	Recent Accounting PronouncementsIn September 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments. The standard provides guidance for estimating credit losses on certain types of financial instruments, including trade receivables, by introducing an approach based on expected losses. The expected loss approach will require entities to incorporate considerations of historical information, current information and reasonable and supportable forecasts. ASU 2016-13 also amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. The Company adopted this standard effective January 1, 2023 under the modified retrospective method whereas comparative period information is not restated. The adoption of this standard did not have a significant impact on the Company’s condensed consolidated financial statements, therefore no cumulative effect or catch up adjustment to the opening balance of retained earnings was recorded.

REVENUE (Tables)

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

Disaggregation of the product revenue by type of customer for the three months ended March 31, 2023 and 2022, respectively:


	Three Months Ended March 31,
		2023		2022
Private sector customers		$	24,013	$	175,844
Public sector entities		481		1,610
Total product revenue		$	24,494	$	177,454

The following table sets forth the Company’s product gross (loss) profit and product gross (loss) profit margin for the three months ended March 31, 2023 and 2022:


	Three Months Ended March 31,
		2023			2022
Product revenue		$	24,494		$	177,454
Cost of product revenue		39,823			86,697
Product gross (loss) profit		$	(15,329)		$	90,757
Product gross (loss) profit margin		(63)		%	51		%

Schedule of Contract Liabilities

The activity related to contract liabilities for the three months ended March 31, 2023 and 2022 is as follows:


	Three Months Ended March 31,
	2023		2022
Balance at beginning of period	$	1,566	$	92,448
Unearned revenue from cash received during the period, excluding amounts recognized as revenue during the period	556		2,464
Revenue recognized related to contract liability balance at the beginning of the period	(1,368)		—
Balance at end of period	$	754	$	94,912

INVENTORIES (Tables)

3 Months Ended

Mar. 31, 2023

Inventory Disclosure [Abstract]

Schedule of Inventories

As of March 31, 2023 and December 31, 2022, the Company’s inventories consisted of the following:


	March 31, 2023		December 31, 2022
Raw materials	$	80,939	$	80,968
Work-in-process	12,647		14,305
Finished goods	45,061		37,867

Reserve	(28,923)		(25,494)
Total inventories	$	109,724	$	107,646
Non-current inventories	$	(27,718)	$	(25,436)
Total inventories, current	$	82,006	$	82,210

PREPAID EXPENSES (Tables)

3 Months Ended

Mar. 31, 2023

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Prepaid Expenses

As of March 31, 2023 and December 31, 2022, the Company’s prepaid expenses consisted of the following:


	March 31, 2023		December 31, 2022
Prepaid expense	$	7,892	$	11,523
Prepaid inventory	3,725		4,205
Total prepaid expenses	$	11,617	$	15,728

PROPERTY AND EQUIPMENT, NET (Tables)

3 Months Ended

Mar. 31, 2023

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment, Net

As of March 31, 2023 and December 31, 2022, the Company’s property and equipment, net consisted of the following:


	March 31, 2023		December 31, 2022
Construction in progress	$	36,101	$	32,412
Machinery and equipment	216,355		214,702
Leasehold improvements	23,343		23,233
Furniture and fixtures	1,911		1,883
Property and equipment	277,710		272,230
Accumulated depreciation and amortization	(93,513)		(82,955)
Total property and equipment, net	$	184,197	$	189,275

INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

As of March 31, 2023 and December 31, 2022, the Company’s intangible assets consisted of the following:


	March 31, 2023		December 31, 2022
Capitalized software	$	18,658	$	19,052
Accumulated amortization	(7,229)		(5,724)
Capitalized software, net	11,429		13,328
In-process software development	8,345		3,539
Total intangible assets	$	19,774	$	16,867

Schedule of Estimated Amortization Expense

Estimated amortization expense for each of the years ending December 31 is as follows:


2023 (excluding the three months ended March 31, 2023)	$	4,409
2024	5,073
2025	1,937
2026	10
Total amortization expense	$	11,429

LEASES (Tables)

3 Months Ended

Mar. 31, 2023

Leases [Abstract]

Schedule of Lease Assets and Liabilities

The right-of-use assets and lease liabilities recognized on the Company’s balance sheet as of March 31, 2023 and December 31, 2022 were as follows:


	Balance Sheet Location	March 31, 2023		December 31, 2022
Assets
Right-of-use assets operating leases	Operating lease right-of-use assets	$	84,542	$	85,321
Right-of-use assets finance leases	Property and equipment, net	6,624		7,264
Liabilities
Operating lease liabilities (current)	Operating lease liabilities, current	7,739		7,739
Finance lease liabilities (current)	Finance lease liabilities, current	2,148		2,362
Operating lease liabilities (non-current)	Operating lease liabilities, net of current portion	42,826		44,045
Finance lease liabilities (non-current)	Finance lease liabilities, net of current portion	417		849

Schedule of Lease Cost

The components of lease expense for the three months ended March 31, 2023 and 2022 were as follows:


	Three Months Ended March 31,
		2023		2022
Operating lease cost		$	2,988	$	2,762
Finance lease cost:
Amortization of right-of-use assets		640		639
Interest on lease liabilities		24		51
Total lease cost		$	3,652	$	3,452

ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2023

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities and Other Current Liabilities

Accrued liabilities and other current liabilities consisted of the following:


	March 31, 2023		December 31, 2022
Accrued purchases(1)	$	2,517	$	4,488
Accrued payroll and benefits	14,211		26,350
Accrued expenses	7,894		5,553
Accrued sales tax	385		1,361
Product warranty reserve (See Note 15. Commitments and Contingencies)	6,584		6,660
Accrued restructuring	365		—
Accrued purchase commitment loss (2)	8,217		7,966
Total accrued liabilities and other current liabilities	$	40,173	$	52,378

(2) Accrued purchase commitment loss reflects accrued loss on purchase obligations for inventory expected to be reserved.

STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of Stock-Based Compensation Expense Related to Awards Issued

Stock-based compensation expense related to awards issued under the Company's incentive compensation plans for the three months ended March 31, 2023 and 2022, was as follows:


	Three Months Ended March 31,
		2023		2022
Cost of product revenues		$	636	$	518
Sales and marketing		1,528		2,813
Research and development		5,069		5,145
General and administrative		6,855		7,559
Restructuring		319		—
Total stock-based compensation expense		$	14,407	$	16,035

Schedule of Stock Option Activity and Related Information

A summary of stock option activity and related information for the three months ended March 31, 2023 was as follows:


	Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)
Outstanding at January 1, 2023	7,102,853	$	5.92	6.4
Granted	3,473,387	2.15
Exercised	(142,141)	0.70
Forfeited	(754,996)	14.37
Expired	(5,500)	15.61
Outstanding at March 31, 2023	9,673,603	$	3.97	7.4
Exercisable at March 31, 2023	5,587,957	$	4.42	5.7
Vested and expected to vest at March 31, 2023	9,673,603	$	3.97	7.4

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions


	2023
Expected volatility	85%
Expected term (years)	6.5
Expected dividend yield	0.0%
Risk-free interest rate	4.3%
Grant date fair value	$	1.58

Schedule of Share-based Payment Arrangement, Restricted Stock Unit, Activity

A summary of RSU activity and related information for the three months ended March 31, 2023 was as follows:


	Underlying Shares	Weighted-average Grant Date Fair Value		Aggregate Fair Value
Outstanding, January 1, 2023	18,681,701	$	9.51	$	177,739
Granted	6,821,951	2.11		14,370
Vested	(864,455)	10.29		(8,893)
Forfeited	(2,038,728)	6.28		(12,797)
Outstanding, March 31, 2023	22,600,469	$	7.54	$	170,419

Market-based performance-vesting RSU activity for the three months ended March 31, 2023 was as follows:


	Underlying Shares		Weighted-average Grant Date Fair Value		Aggregate Fair Value
Outstanding, January 1, 2023	$	3,335,300	$	12.82	$	42,759
Granted	—		—		—
Vested	—		—		—
Forfeited	—		—		—
Outstanding, March 31, 2023	$	3,335,300	$	12.82	$	42,759

Operations-based performance-vesting RSU activity for the three months ended March 31, 2023 was as follows:


	Underlying Shares	Weighted-average Grant Date Fair Value		Aggregate Fair Value
Outstanding, January 1, 2023	798,635	$	16.00	$	12,778
Granted	266,212	2.48		660
Vested	—	—		—
Forfeited	(266,212)	2.48		(660)
Outstanding, March 31, 2023	798,635	$	16.00	$	12,778

INCOME (LOSS) PER SHARE (Tables)

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

Schedule of Net Income (Loss) Per Share, Basic and Diluted

The following table reconciles net (loss) income and the weighted-average shares used in computing basic and diluted earnings per share:


	Three Months Ended March 31,
		2023		2022
Numerator:
Net (loss) income		$	(94,198)	$	2,803






Denominator:
Basic weighted-average common shares outstanding		151,083,716		146,526,370
Dilutive potential common stock issuable:
Common stock warrants		—		72,395

Stock options		—		5,813,101
Restricted stock units		—		624,938
Diluted weighted-average shares outstanding		151,083,716		153,036,804

Net (loss) income per share
Basic		$	(0.62)	$	0.02
Diluted		$	(0.62)	$	0.02

Schedule of Antidilutive Securities Excluded from Computation of Net Income (Loss) Per Share

Outstanding anti-dilutive securities not included in the diluted net income (loss) per share attributable to common stockholders calculations were as follows (in common stock equivalent shares):


	Three Months Ended March 31,
		2023	2022

Stock options		9,673,603	2,701,855
Restricted stock units		22,600,469	9,634,182



Employee stock purchase plan – shares projected to be issued		564,413	110,935
Total		32,838,485	12,446,972

COMMITMENTS AND CONTINGENCIES (Tables)

3 Months Ended

Mar. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Schedule of Product Warranty Liability

The following table provides a reconciliation of the change in estimated warranty liabilities:


	Amount
Balance, December 31, 2022	$	6,660
Provision for warranties	3,322
Settlements	(3,398)
Balance, March 31, 2023	$	6,584

Summary of Total Amount Incurred and Accrued Related to Restructuring Activities

The following table summarizes the total amount incurred and accrued related to these restructuring activities:


	Amount
Accrued restructuring as of December 31, 2022	$	—
Restructuring charges incurred during the period	7,873
Cash payments	(7,247)
Non-cash settlements and other adjustments	(261)
Accrued restructuring as of March 31, 2023	$	365

BUSINESS AND BASIS OF ACCOUNTING (Details) $ in Millions	3 Months Ended
BUSINESS AND BASIS OF ACCOUNTING (Details) $ in Millions	Mar. 31, 2023 USD ($) segment	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Class of Stock [Line Items]
Number of operating segments \| segment	1
Non-US
Class of Stock [Line Items]
Revenue	$ 0.0	$ 3.5
Long-lived assets	$ 4.4		$ 4.7

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

REVENUE - Schedule of Product Revenue By Customer Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 24,765	$ 179,410
Product revenue
Disaggregation of Revenue [Line Items]
Revenue	24,494	177,454
Product revenue \| Private sector customers
Disaggregation of Revenue [Line Items]
Revenue	24,013	175,844
Product revenue \| Public sector entities
Disaggregation of Revenue [Line Items]
Revenue	$ 481	$ 1,610

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

REVENUE - Schedule of Product Revenue Gross (Loss) Profit and Gross (Loss) Profit Margin (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Product revenue	$ 24,765	$ 179,410
Product revenue
Disaggregation of Revenue [Line Items]
Product revenue	24,494	177,454
Cost of product revenue	39,823	86,697
Product gross (loss) profit	$ (15,329)	$ 90,757
Product gross (loss) profit margin	(63.00%)	51.00%

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

+ Details

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

REVENUE - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
REVENUE - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Inventory write-down	$ 12,000
Net contract assets	0		$ 300
Revenue	24,765	$ 179,410
Accounts receivable, allowance for doubtful accounts	2,000		$ 2,300
Grant and other revenue
Disaggregation of Revenue [Line Items]
Revenue	271	1,956
Grant and other revenue \| Biomedical Advanced Research And Development Authority (BARDA)
Disaggregation of Revenue [Line Items]
Revenue	$ 100	$ 2,000

- Definition

+ References

+ Details

REVENUE - Schedule of Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Contract With Customer, Liability Rollforward [Roll Forward]
Balance at beginning of period	$ 1,566	$ 92,448
Unearned revenue from cash received during the period, excluding amounts recognized as revenue during the period	556	2,464
Revenue recognized related to contract liability balance at the beginning of the period	(1,368)	0
Balance at end of period	$ 754	$ 94,912

INVENTORIES - Schedule of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 80,939	$ 80,968
Work-in-process	12,647	14,305
Finished goods	45,061	37,867
Reserve	(28,923)	(25,494)
Total inventories	109,724	107,646
Non-current inventories	(27,718)	(25,436)
Total inventories, current	$ 82,006	$ 82,210

PREPAID EXPENSES - Schedule of Prepaid Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expense	$ 7,892	$ 11,523
Prepaid inventory	3,725	4,205
Total prepaid expenses	$ 11,617	$ 15,728

PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment	$ 277,710	$ 272,230
Accumulated depreciation and amortization	(93,513)	(82,955)
Total property and equipment, net	184,197	189,275
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment	36,101	32,412
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment	216,355	214,702
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment	23,343	23,233
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment	$ 1,911	$ 1,883

PROPERTY AND EQUIPMENT, NET - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Depreciation	$ 10,600	$ 10,000
Carrying value of finance leases	6,624		$ 7,264
Manufacturing Equipment
Property, Plant and Equipment [Line Items]
Construction in progress	$ 23,800

INTANGIBLE ASSETS - Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Capitalized software	$ 18,658	$ 19,052
Accumulated amortization	(7,229)	(5,724)
Capitalized software, net	11,429	13,328
Total intangible assets	19,774	16,867
In-process software development
Finite-Lived Intangible Assets [Line Items]
In-process software development	$ 8,345	$ 3,539

INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 1.6	$ 0.6

INTANGIBLE ASSETS - Schedule of Estimated Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	$ 19,774	$ 16,867
Software
Finite-Lived Intangible Assets [Line Items]
2023 (excluding the three months ended March 31, 2023)	4,409
2024	5,073
2025	1,937
2026	10
Total intangible assets	$ 11,429

LEASES - Narrative (Details)	Mar. 31, 2023
Minimum
Lessee, Lease, Description [Line Items]
Finance lease, remaining lease term (in years)	1 year
Operating lease, remaining lease term (in years)	1 year
Maximum
Lessee, Lease, Description [Line Items]
Finance lease, remaining lease term (in years)	2 years
Operating lease, remaining lease term (in years)	9 years

LEASES - Schedule of Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets
Operating lease right-of-use assets	$ 84,542	$ 85,321
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and equipment, net	Property and equipment, net
Right-of-use assets finance leases	$ 6,624	$ 7,264
Liabilities
Operating lease liabilities (current)	7,739	7,739
Finance lease liabilities (current)	2,148	2,362
Operating lease liabilities (non-current)	42,826	44,045
Finance lease liabilities (non-current)	$ 417	$ 849

LEASES - Schedule of Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases [Abstract]
Operating lease cost	$ 2,988	$ 2,762
Finance lease cost:
Amortization of right-of-use assets	640	639
Interest on lease liabilities	24	51
Total lease cost	$ 3,652	$ 3,452

ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued purchases	$ 2,517	$ 4,488
Accrued payroll and benefits	14,211	26,350
Accrued expenses	7,894	5,553
Accrued sales tax	385	1,361
Product warranty reserve	6,584	6,660
Accrued restructuring	365	0
Accrued purchase commitment loss	8,217	7,966
Total accrued liabilities and other current liabilities	$ 40,173	$ 52,378

DEBT (Details) $ in Thousands	Jun. 30, 2022 USD ($)	Mar. 31, 2023 USD ($)
Revolving Credit Facility \| Line of Credit
Debt Instrument [Line Items]
Debt covenant, percent of eligible accounts receivable less sales tax liability	80.00%
Revolving Credit Facility \| Line of Credit \| Maximum
Debt Instrument [Line Items]
Asset coverage ratio	1.20
Revolving Credit Facility \| Line of Credit \| Minimum
Debt Instrument [Line Items]
Asset coverage ratio	1.00
Revolving Credit Facility \| Secured Revolving Facility Agreement \| East West Bank \| Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 100,000
Line of credit		$ 0
Remaining borrowing capacity		99,000
Revolving Credit Facility \| Revolving Credit Agreement \| Line of Credit
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	3.50%
Prepayment fee	1.00%
Interest rate, increase	2.00%
Revolving Credit Facility \| Revolving Credit Agreement \| Line of Credit \| Maximum
Debt Instrument [Line Items]
Current ratio	1.20
Revolving Credit Facility \| Revolving Credit Agreement \| Line of Credit \| Minimum
Debt Instrument [Line Items]
Current ratio	1.00
Letter of Credit \| Secured Revolving Facility Agreement \| Line of Credit
Debt Instrument [Line Items]
Deferred financing cost		600
Letter of Credit \| Secured Revolving Facility Agreement \| East West Bank \| Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 20,000
Letter of Credit \| Revolving Credit Agreement
Debt Instrument [Line Items]
Letters of credit outstanding		$ 1,000

CAPITAL STOCK (Details) - Common Stock Warrants	Mar. 31, 2023 $ / shares shares
Class of Stock [Line Items]
Warrants outstanding (in shares) \| shares	75,744
Exercise price of warrant (in dollars per share) \| $ / shares	$ 0.40

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		12 Months Ended
	Sep. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining contractual term (years), outstanding		7 years 4 months 24 days		6 years 4 months 24 days
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized share-based compensation cost related to unvested stock option awards		$ 11.3
Expected period for recognition		2 years 7 months 6 days
Granted (in shares)		622,323
Plan modification, incremental cost		$ 0.4
Share-based Payment Arrangement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation cost capitalized in inventory			$ 0.6
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		6,821,951
Award vesting period		4 years
Award vesting percentage		25.00%
Unrecognized compensation cost		$ 123.5
Weighted average remaining contractual term (years), outstanding		2 years 10 months 24 days
Operations-Based Performance-Vesting RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	1,597,272	266,212
2021 Stock Purchase Plan \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual percentage increase in shares available	5.00%
2021 Stock Purchase Plan \| Stock options \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)	22,399,691
2021 Employee Stock Purchase Plan \| Employee stock purchase plan – shares projected to be issued
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)	2,834,754
Annual percentage increase in shares available	1.00%
Annual increase, number of shares (in shares)	8,504,263
Purchase price of common stock, percent	85.00%

STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense Related to Awards Issued (Details) - Share-based Payment Arrangement - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 14,407	$ 16,035
Cost of product revenues
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	636	518
Sales and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	1,528	2,813
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	5,069	5,145
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	6,855	7,559
Restructuring
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 319	$ 0

STOCK-BASED COMPENSATION - Schedule of Stock Option Activity and Related Information (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Options
Outstanding at beginning of period (in shares)	7,102,853
Granted (in shares)	3,473,387
Exercised (in shares)	(142,141)
Forfeited (in shares)	(754,996)
Expired (in shares)	(5,500)
Outstanding at end of period (in shares)	9,673,603	7,102,853
Weighted Average Exercise Price
Outstanding at beginning of period (in dollars per share)	$ 5.92
Granted (in dollars per share)	2.15
Exercised (in dollars per share)	0.70
Forfeited (in dollars per share)	14.37
Expired (in dollars per share)	15.61
Outstanding at end of period (in dollars per share)	$ 3.97	$ 5.92
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options, exercisable (in shares)	5,587,957
Options, vested and expected to vest (in shares)	9,673,603
Weighted average exercise price, exercisable (in dollars per share)	$ 4.42
Weighted average exercise price, vested and expected to vest (in dollars per share)	$ 3.97
Weighted average remaining contractual term (years), outstanding	7 years 4 months 24 days	6 years 4 months 24 days
Weighted average remaining contractual term (years), exercisable	5 years 8 months 12 days
Weighted average remaining contractual term (years), vested and expected to vest	7 years 4 months 24 days

STOCK-BASED COMPENSATION - Valuation Assumptions (Details) - Stock options	3 Months Ended
	Mar. 31, 2023 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	85.00%
Expected term (years)	6 years 6 months
Expected dividend yield	0.00%
Risk-free interest rate	4.30%
Grant date fair value (in dollars per share)	$ 1.58

STOCK-BASED COMPENSATION - Schedule of Share-based Payment Arrangement, Restricted Stock Unit, Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Sep. 30, 2021	Mar. 31, 2023
Restricted stock units
Underlying Shares
Outstanding, beginning balance (in shares)		18,681,701
Granted (in shares)		6,821,951
Vested (in shares)		(864,455)
Forfeited (in shares)		(2,038,728)
Outstanding, ending balance (in shares)		22,600,469
Weighted-average Grant Date Fair Value
Outstanding, beginning balance(in dollars per share)		$ 9.51
Granted (in dollars per share)		2.11
Vested (in dollars per share)		10.29
Forfeited (in dollars per share)		6.28
Outstanding, ending balance (in dollars per share)		$ 7.54
Aggregate Fair Value
Aggregate fair value, beginning balance		$ 177,739
Granted		14,370
Vested		(8,893)
Forfeited		(12,797)
Aggregate fair value, ending balance		$ 170,419
Market-Based Performance-Vesting RSUs
Underlying Shares
Outstanding, beginning balance (in shares)		3,335,300
Granted (in shares)	3,335,300	0
Vested (in shares)		0
Forfeited (in shares)		0
Outstanding, ending balance (in shares)		3,335,300
Weighted-average Grant Date Fair Value
Outstanding, beginning balance(in dollars per share)		$ 12.82
Granted (in dollars per share)		0
Vested (in dollars per share)		0
Forfeited (in dollars per share)		0
Outstanding, ending balance (in dollars per share)		$ 12.82
Aggregate Fair Value
Aggregate fair value, beginning balance		$ 42,759
Granted		0
Vested		0
Forfeited		0
Aggregate fair value, ending balance		$ 42,759
Operations-Based Performance-Vesting RSUs
Underlying Shares
Outstanding, beginning balance (in shares)		798,635
Granted (in shares)	1,597,272	266,212
Vested (in shares)		0
Forfeited (in shares)		(266,212)
Outstanding, ending balance (in shares)		798,635
Weighted-average Grant Date Fair Value
Outstanding, beginning balance(in dollars per share)		$ 16.00
Granted (in dollars per share)		2.48
Vested (in dollars per share)		0
Forfeited (in dollars per share)		2.48
Outstanding, ending balance (in dollars per share)		$ 16.00
Aggregate Fair Value
Aggregate fair value, beginning balance		$ 12,778
Granted		660
Vested		0
Forfeited		(660)
Aggregate fair value, ending balance		$ 12,778

INCOME (LOSS) PER SHARE - Schedule of Net Income (Loss) Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator:
Net (loss) income	$ (94,198)	$ 2,803
Denominator:
Basic weighted-average common shares outstanding (in shares)	151,083,716	146,526,370
Dilutive potential common stock issuable:
Diluted weighted-average shares outstanding (in shares)	151,083,716	153,036,804
Net (loss) income per share
Basic (in dollars per share)	$ (0.62)	$ 0.02
Diluted (in dollars per share)	$ (0.62)	$ 0.02
Stock options
Dilutive potential common stock issuable:
Stock options and restricted stock units (in shares)	0	5,813,101
Restricted stock units
Dilutive potential common stock issuable:
Stock options and restricted stock units (in shares)	0	624,938
Common Stock
Dilutive potential common stock issuable:
Stock warrants (in shares)	0	72,395

INCOME (LOSS) PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Income (Loss) Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	32,838,485	12,446,972
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	9,673,603	2,701,855
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	22,600,469	9,634,182
Employee stock purchase plan – shares projected to be issued
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	564,413	110,935

INCOME TAXES (Details)	3 Months Ended
INCOME TAXES (Details)	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Effective income tax rate	0.00%	0.00%

COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($) $ in Thousands			3 Months Ended
	May 04, 2023	Apr. 28, 2023	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022	Nov. 30, 2021
Debt Instrument [Line Items]
Standard product warranty, term			12 months
Restructuring expense			$ 7,873	$ 0
Restricted cash						$ 800
Forecast \| CHP HC LLP \| TrustMedRx LLC
Debt Instrument [Line Items]
Payment to acquire business	$ 700
Cost Reduction Plan
Debt Instrument [Line Items]
Restructuring expense			7,900
Minimum \| Cost Reduction Plan \| Forecast
Debt Instrument [Line Items]
Severance costs		$ 5,000
Maximum \| Cost Reduction Plan \| Forecast
Debt Instrument [Line Items]
Severance costs		$ 7,000
Revolving Credit Facility \| Secured Revolving Facility Agreement \| East West Bank \| Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity					$ 100,000
Remaining borrowing capacity			99,000
Letter of Credit \| Revolving Credit Agreement
Debt Instrument [Line Items]
Letters of credit outstanding			$ 1,000
Letter of Credit \| Secured Revolving Facility Agreement \| East West Bank \| Line of Credit
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity					$ 20,000

COMMITMENTS AND CONTINGENCIES - Schedule of Product Warranty Liability (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance, December 31, 2022	$ 6,660
Provision for warranties	3,322
Settlements	(3,398)
Balance, March 31, 2023	$ 6,584

COMMITMENTS AND CONTINGENCIES - Restructuring Activities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Restructuring Reserve [Roll Forward]
Accrued restructuring as of December 31, 2022	$ 0
Restructuring charges incurred during the period	7,873
Cash payments	(7,247)
Non-cash settlements and other adjustments	(261)
Accrued restructuring as of March 31, 2023	$ 365